Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung

Detalles Bibliográficos
Autores principales: Jiao, Yuyan, Liu, Ming, Luo, Ningning, Guo, Hao, Li, Jianzhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474472/
https://www.ncbi.nlm.nih.gov/pubmed/34589958
http://dx.doi.org/10.1016/j.jtocrr.2020.100079
_version_ 1784575231620284416
author Jiao, Yuyan
Liu, Ming
Luo, Ningning
Guo, Hao
Li, Jianzhe
author_facet Jiao, Yuyan
Liu, Ming
Luo, Ningning
Guo, Hao
Li, Jianzhe
author_sort Jiao, Yuyan
collection PubMed
description
format Online
Article
Text
id pubmed-8474472
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84744722021-09-28 Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung Jiao, Yuyan Liu, Ming Luo, Ningning Guo, Hao Li, Jianzhe JTO Clin Res Rep Case Report Elsevier 2020-07-24 /pmc/articles/PMC8474472/ /pubmed/34589958 http://dx.doi.org/10.1016/j.jtocrr.2020.100079 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Jiao, Yuyan
Liu, Ming
Luo, Ningning
Guo, Hao
Li, Jianzhe
Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung
title Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung
title_full Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung
title_fullStr Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung
title_full_unstemmed Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung
title_short Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung
title_sort novel mrpl13-alk and ppp1cb-alk double fusion as a potential mechanism of acquired resistance to first-line osimertinib in egfr-mutant high-grade neuroendocrine tumor of the lung
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474472/
https://www.ncbi.nlm.nih.gov/pubmed/34589958
http://dx.doi.org/10.1016/j.jtocrr.2020.100079
work_keys_str_mv AT jiaoyuyan novelmrpl13alkandppp1cbalkdoublefusionasapotentialmechanismofacquiredresistancetofirstlineosimertinibinegfrmutanthighgradeneuroendocrinetumorofthelung
AT liuming novelmrpl13alkandppp1cbalkdoublefusionasapotentialmechanismofacquiredresistancetofirstlineosimertinibinegfrmutanthighgradeneuroendocrinetumorofthelung
AT luoningning novelmrpl13alkandppp1cbalkdoublefusionasapotentialmechanismofacquiredresistancetofirstlineosimertinibinegfrmutanthighgradeneuroendocrinetumorofthelung
AT guohao novelmrpl13alkandppp1cbalkdoublefusionasapotentialmechanismofacquiredresistancetofirstlineosimertinibinegfrmutanthighgradeneuroendocrinetumorofthelung
AT lijianzhe novelmrpl13alkandppp1cbalkdoublefusionasapotentialmechanismofacquiredresistancetofirstlineosimertinibinegfrmutanthighgradeneuroendocrinetumorofthelung

Ejemplares similares